Down the line from genome-wide association studies in inflammatory bowel disease: the resulting clinical benefits and the outlook for the future

References

• Molodecky N, Soon I, Rabi D, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142(1):46-54
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Fried M, Krabshuis JH, et al. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis 2010;16(1):112-24
   PubMed Web of Science ®Google Scholar
• Sands BE. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology 2004;126(6):1518-32
   PubMed Web of Science ®Google Scholar
• Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142(1):46-54.e42. quiz e30
   PubMed Web of Science ®Google Scholar
• O’Toole A, Korzenik J. Environmental triggers for IBD. Curr Gastroenterol Rep 2014;16(7):396
   PubMedGoogle Scholar
• Nagalingam NA, Lynch S V. Role of the microbiota in inflammatory bowel diseases. Inflamm Bowel Dis 2012;18(5):968-84
   PubMed Web of Science ®Google Scholar
• Manichanh C, Borruel N, Casellas F, Guarner F. The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol 2012;9(10):599-608
   PubMed Web of Science ®Google Scholar
• Leone V, Chang EB, Devkota S. Diet, microbes, and host genetics: the perfect storm in inflammatory bowel diseases. J Gastroenterol 2013;48(3):315-21
   PubMed Web of Science ®Google Scholar
• Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 2014;146(6):1489-99
   PubMed Web of Science ®Google Scholar
• Brant SR. Update on the heritability of inflammatory bowel disease: the importance of twin studies. Inflamm Bowel Dis 2011;17(1):1-5
   PubMed Web of Science ®Google Scholar
• Hugot JP, Laurent-Puig P, Gower-Rousseau C, et al. Mapping of a susceptibility locus for Crohn’s disease on chromosome 16. Nature 1996;379(6568):821-3
   PubMed Web of Science ®Google Scholar
• Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 2001;411(6837):599-603
   PubMed Web of Science ®Google Scholar
• Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature 2001;411(6837):603-6
   PubMed Web of Science ®Google Scholar
• Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007;447(7145):661-78
   PubMed Web of Science ®Google Scholar
• Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011;43(3):246-52
   PubMed Web of Science ®Google Scholar
• Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012;491(7422):119-24
   PubMed Web of Science ®Google Scholar
• Lakatos PL, Lakatos L, Kiss LS, et al. Treatment of extraintestinal manifestations in inflammatory bowel disease. Digestion 2012;86(Suppl 1):28-35
   PubMed Web of Science ®Google Scholar
• Ott C, Schölmerich J. Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol 2013;10(10):585-95
   PubMed Web of Science ®Google Scholar
• Turnbull GK, Vallis TM. Quality of life in inflammatory bowel disease: the interaction of disease activity with psychosocial function. Am J Gastroenterol 1995;90(9):1450-4
   PubMed Web of Science ®Google Scholar
• Blumberg RS, Dittel B, Hafler D, et al. Unraveling the autoimmune translational research process layer by layer. Nat Med 2012;18(1):35-41
   PubMed Web of Science ®Google Scholar
• Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011;60(5):571-607
   PubMed Web of Science ®Google Scholar
• Frolkis AD, Dykeman J, Negrón ME, et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology 2013;145(5):996-1006
   PubMed Web of Science ®Google Scholar
• D’Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 2008;371(9613):660-7
   PubMed Web of Science ®Google Scholar
• Imielinski M, Baldassano RN, Griffiths A, et al. Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet 2009;41(12):1335-40
   PubMed Web of Science ®Google Scholar
• Kugathasan S, Baldassano RN, Bradfield JP, et al. Loci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel disease. Nat Genet 2008;40(10):1211-15
   PubMed Web of Science ®Google Scholar
• Golovics PA, Mandel MD, Lovasz BD, Lakatos PL. Inflammatory bowel disease course in Crohn’s disease: is the natural history changing? World J Gastroenterol 2014;20(12):3198-207
   PubMed Web of Science ®Google Scholar
• Mathew CG, Lewis CM. Genetics of inflammatory bowel disease: progress and prospects. Hum Mol Genet 2004;13 Spec No:R161-8
   Google Scholar
• Cuthbert AP, Fisher SA, Mirza MM, et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology 2002;122(4):867-74
   PubMed Web of Science ®Google Scholar
• Sachidanandam R, Weissman D, Schmidt SC, et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001;409(6822):928-33
   PubMed Web of Science ®Google Scholar
• Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 2001;409(6822):860-921
   PubMed Web of Science ®Google Scholar
• Rothman KJ, Greenland S, Lash TL. Modern Epidemiology. Khoury MJ, Millikan R, Gwinn M, editors, 3rd Edition. Genetic and Molecular Epidemiology. Lippincott, Williams & Wilkins; Philadelphia, PA: 2008
   Google Scholar
• Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006;314(5804):1461-3
   PubMed Web of Science ®Google Scholar
• Hampe J, Franke A, Rosenstiel P, et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet 2007;39(2):207-11
   PubMed Web of Science ®Google Scholar
• Parkes M, Barrett JC, Prescott NJ, et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn’s disease susceptibility. Nat Genet 2007;39(7):830-2
   PubMed Web of Science ®Google Scholar
• WTCCC. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007;447(7145):661-78
   PubMed Web of Science ®Google Scholar
• Fisher SA, Tremelling M, Anderson CA, et al. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn’s disease. Nat Genet 2008;40(6):710-12
   PubMed Web of Science ®Google Scholar
• Silverberg MS, Cho JH, Rioux JD, et al. Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. Nat Genet 2009;41(2):216-20
   PubMed Web of Science ®Google Scholar
• Franke A, Balschun T, Karlsen TH, et al. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet 2008;40(11):1319-23
   PubMed Web of Science ®Google Scholar
• Festen EAM, Stokkers PCF, van Diemen CC, et al. Genetic analysis in a Dutch study sample identifies more ulcerative colitis susceptibility loci and shows their additive role in disease risk. Am J Gastroenterol 2010;105(2):395-402
   PubMed Web of Science ®Google Scholar
• Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat Genet 2008;40(8):955-62
   PubMed Web of Science ®Google Scholar
• IIBDGC. Available from: www.ibdgenetics.org/
   Google Scholar
• Franke A, McGovern DPB, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat Genet 2010;42(12):1118-25
   PubMed Web of Science ®Google Scholar
• Lees CW, Barrett JC, Parkes M, Satsangi J. New IBD genetics: common pathways with other diseases. Gut 2011;60(12):1739-53
   PubMed Web of Science ®Google Scholar
• Zhernakova A, van Diemen CC, Wijmenga C. Detecting shared pathogenesis from the shared genetics of immune-related diseases. Nat Rev Genet 2009;10(1):43-55
   PubMed Web of Science ®Google Scholar
• Trynka G, Hunt KA, Bockett NA, et al. Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease. Nat Genet 2011;43(12):1193-201
   PubMed Web of Science ®Google Scholar
• Cortes A, Brown MA. Promise and pitfalls of the Immunochip. Arthritis Res Ther 2011;13(1):101
   PubMed Web of Science ®Google Scholar
• Visscher PM, Brown MA, McCarthy MI, Yang J. Five years of GWAS discovery. Am J Hum Genet 2012;90(1):7-24
   PubMed Web of Science ®Google Scholar
• Chen G-B, Lee SH, Brion M-JA, et al. Estimation and partitioning of (co)heritability of inflammatory bowel disease from GWAS and immunochip data. Hum Mol Genet 2014;23(17):4710-20
   PubMed Web of Science ®Google Scholar
• Diaz-Gallo L-M, Espino-Paisán L, Fransen K, et al. Differential association of two PTPN22 coding variants with Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis 2011;17(11):2287-94
   PubMed Web of Science ®Google Scholar
• Parkes M, Cortes A, van Heel DA, Brown MA. Genetic insights into common pathways and complex relationships among immune-mediated diseases. Nat Rev Genet 2013;14(9):661-73
   PubMed Web of Science ®Google Scholar
• Festen EAM, Goyette P, Green T, et al. A meta-analysis of genome-wide association scans identifies IL18RAP, PTPN2, TAGAP, and PUS10 as shared risk loci for Crohn’s disease and celiac disease. PLoS Genet 2011;7(1):e1001283
   PubMed Web of Science ®Google Scholar
• Van Limbergen J, Radford-Smith G, Satsangi J. Advances in IBD genetics. Nat Rev Gastroenterol Hepatol 2014;11(6):372-85
   PubMed Web of Science ®Google Scholar
• Girardin SE, Boneca IG, Viala J, et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003;278(11):8869-72
   PubMed Web of Science ®Google Scholar
• Couturier-Maillard A, Secher T, Rehman A, et al. NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. J Clin Invest 2013;123(2):700-11
   PubMed Web of Science ®Google Scholar
• Kobayashi KS, Chamaillard M, Ogura Y, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005;307(5710):731-4
   PubMed Web of Science ®Google Scholar
• Philpott DJ, Sorbara MT, Robertson SJ, et al. NOD proteins: regulators of inflammation in health and disease. Nat Rev Immunol 2014;14(1):9-23
   PubMed Web of Science ®Google Scholar
• Lipinski S, Grabe N, Jacobs G, et al. RNAi screening identifies mediators of NOD2 signaling: implications for spatial specificity of MDP recognition. Proc Natl Acad Sci USA 2012;109(52):21426-31
   PubMed Web of Science ®Google Scholar
• Adler J, Rangwalla SC, Dwamena BA, Higgins PDR. The prognostic power of the NOD2 genotype for complicated Crohn’s disease: a meta-analysis. Am J Gastroenterol 2011;106(4):699-712
   PubMed Web of Science ®Google Scholar
• Van Limbergen J, Kabakchiev B, Stempak JM, et al. Hypothesis-free analysis of ATG16L1 demonstrates gene-wide extent of association with Crohn’s disease susceptibility. Gut 2013;62(2):331-3
   PubMed Web of Science ®Google Scholar
• Rioux JD, Xavier RJ, Taylor KD, et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet 2007;39(5):596-604
   PubMed Web of Science ®Google Scholar
• Hussey S, Travassos LH, Jones NL. Autophagy as an emerging dimension to adaptive and innate immunity. Semin Immunol 2009;21(4):233-41
   PubMed Web of Science ®Google Scholar
• Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature 2008;451(7182):1069-75
   PubMed Web of Science ®Google Scholar
• Travassos LH, Carneiro LAM, Ramjeet M, et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol 2010;11(1):55-62
   PubMed Web of Science ®Google Scholar
• Cooney R, Baker J, Brain O, et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med 2010;16(1):90-7
   PubMed Web of Science ®Google Scholar
• Orvedahl A, Sumpter R, Xiao G, et al. Image-based genome-wide siRNA screen identifies selective autophagy factors. Nature 2011;480(7375):113-17
   PubMed Web of Science ®Google Scholar
• McGovern D, Powrie F. The IL23 axis plays a key role in the pathogenesis of IBD. Gut 2007;56(10):1333-6
   PubMed Web of Science ®Google Scholar
• Hue S, Ahern P, Buonocore S, et al. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J Exp Med 2006;203(11):2473-83
   PubMed Web of Science ®Google Scholar
• Brand S. Crohn’s disease: th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn’s disease. Gut 2009;58(8):1152-67
   PubMed Web of Science ®Google Scholar
• Yu RY, Gallagher G. A naturally occurring, soluble antagonist of human IL-23 inhibits the development and in vitro function of human Th17 cells. J Immunol 2010;185(12):7302-8
   PubMed Web of Science ®Google Scholar
• Coskun M, Salem M, Pedersen J, Nielsen OH. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. Pharmacol Res 2013;76:1-8
   PubMed Web of Science ®Google Scholar
• Brand S, Beigel F, Olszak T, et al. IL-22 is increased in active Crohn’s disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am J Physiol Gastrointest Liver Physiol 2006;290(4):G827-38
   PubMed Web of Science ®Google Scholar
• Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003;52(1):65-70
   PubMed Web of Science ®Google Scholar
• Annunziato F, Cosmi L, Santarlasci V, et al. Phenotypic and functional features of human Th17 cells. J Exp Med 2007;204(8):1849-61
   PubMed Web of Science ®Google Scholar
• Seiderer J, Elben I, Diegelmann J, et al. Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn’s disease and analysis of the IL17F p.His161Arg polymorphism in IBD. Inflamm Bowel Dis 2008;14(4):437-45
   PubMed Web of Science ®Google Scholar
• Dambacher J, Beigel F, Zitzmann K, et al. The role of the novel Th17 cytokine IL-26 in intestinal inflammation. Gut 2009;58(9):1207-17
   PubMed Web of Science ®Google Scholar
• Christophi GP, Rong R, Holtzapple PG, et al. Immune markers and differential signaling networks in ulcerative colitis and Crohn’s disease. Inflamm Bowel Dis 2012;18(12):2342-56
   PubMed Web of Science ®Google Scholar
• Fransen K, Mitrovic M, van Diemen CC, Weersma RK. The quest for genetic risk factors for Crohn’s disease in the post-GWAS era. Genome Med 2011;3(2):13
   PubMed Web of Science ®Google Scholar
• Weersma RK, Stokkers PCF, van Bodegraven AA, et al. Molecular prediction of disease risk and severity in a large Dutch Crohn’s disease cohort. Gut 2009;58(3):388-95
   PubMed Web of Science ®Google Scholar
• Hou JK, Lee D, Lewis J. Diet and Inflammatory Bowel Disease: review of Patient-Targeted Recommendations. Clin Gastroenterol Hepatol 2014;12(10):1592-600
   PubMed Web of Science ®Google Scholar
• Plenge RM, Scolnick EM, Altshuler D. Validating therapeutic targets through human genetics. Nat Rev Drug Discov 2013;12(8):581-94
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology 2008;135(4):1130-41
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Gasink C, Gao L-L, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med 2012;367(16):1519-28
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012;367(7):616-24
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Ghosh S, Panes J, et al. A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Crohn’s Disease. Clin Gastroenterol Hepatol 2014;12(9):1485-93.e2
   PubMed Web of Science ®Google Scholar
• Reinisch W, Panés J, Lémann M, et al. A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn’s disease. Am J Gastroenterol 2008;103(9):2284-92
   PubMed Web of Science ®Google Scholar
• Massey DCO, Bredin F, Parkes M. Use of sirolimus (rapamycin) to treat refractory Crohn’s disease. Gut 2008;57(9):1294-6
   PubMed Web of Science ®Google Scholar
• Sakuraba A, Annunziata ML, Cohen RD, et al. Mucosal healing is associated with improved long-term outcome of maintenance therapy with natalizumab in Crohn’s disease. Inflamm Bowel Dis 2013;19(12):2577-83
   PubMed Web of Science ®Google Scholar
• Juillerat P, Wasan SK, Fowler SA, et al. Efficacy and safety of natalizumab in Crohn’s disease patients treated at 6 Boston academic hospitals. Inflamm Bowel Dis 2013;19(11):2457-63
   PubMed Web of Science ®Google Scholar
• Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006;354(9):924-33
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2013;369(8):711-21
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369(8):699-710
   PubMed Web of Science ®Google Scholar
• Thomas S, Baumgart DC. Targeting leukocyte migration and adhesion in Crohn’s disease and ulcerative colitis. Inflammopharmacology 2012;20(1):1-18
   PubMedGoogle Scholar
• Lacey DL, Boyle WJ, Simonet WS, et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov 2012;11(5):401-19
   PubMed Web of Science ®Google Scholar
• Häusler KD, Horwood NJ, Chuman Y, et al. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation. J Bone Miner Res 2004;19(11):1873-81
   PubMed Web of Science ®Google Scholar
• Tilg H, Moschen AR, Kaser A, et al. Gut, inflammation and osteoporosis: basic and clinical concepts. Gut 2008;57(5):684-94
   PubMed Web of Science ®Google Scholar
• Yang S-K, Hong M, Baek J, et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet 2014;46(9):1017-20
   PubMed Web of Science ®Google Scholar
• Heap GA, Weedon MN, Bewshea CM, et al. HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nat Genet 2014;46(10):1131-4
   PubMed Web of Science ®Google Scholar
• International SAE Consortium. Available from: www.saeconsortium.org
   Google Scholar
• Cleynen I, González JR, Figueroa C, et al. Genetic factors conferring an increased susceptibility to develop Crohn’s disease also influence disease phenotype: results from the IBDchip European Project. Gut 2013;62(11):1556-65
   PubMed Web of Science ®Google Scholar
• Cleynen I, Mahachie John JM, Henckaerts L, et al. Molecular reclassification of Crohn’s disease by cluster analysis of genetic variants. PLoS One 2010;5(9):e12952
   PubMed Web of Science ®Google Scholar
• PSI. Available from: www.string-of-pearls.org
   Google Scholar
• Morgan XC, Tickle TL, Sokol H, et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 2012;13(9):R79
   PubMed Web of Science ®Google Scholar
• Gevers D, Kugathasan S, Denson LA, et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe 2014;15(3):382-92
   PubMed Web of Science ®Google Scholar
• Huttenhower C, Kostic AD, Xavier RJ. Inflammatory Bowel Disease as a Model for Translating the Microbiome. Immunity 2014;40(6):843-54
   PubMed Web of Science ®Google Scholar